Correvio

Correvio Pharma Corp. is a specialty pharmaceutical company that focuses on the commercialization of treatments for acute coronary syndromes, atrial fibrillation, and bacterial infections. The company operates in the healthcare sector, primarily targeting hospitals and healthcare providers. Correvio's business model revolves around the development, acquisition, and commercialization of pharmaceutical products. The company generates revenue through the sale of its commercialized products, which include Aggrastat, Brinavess, and XYDALBA, as well as through partnerships and licensing agreements. Correvio serves a global market, with a particular focus on North America, Europe, and Asia. The company's strategic partnerships, such as the one with Hong Kong Teson Pharma Limited for commercialization in China, further expand its market reach. Correvio's product pipeline includes TREVYENT, which is in development for the treatment of pulmonary arterial hypertension. The company aims to improve patient health by providing effective and innovative treatments for serious medical conditions.

Keywords: specialty pharmaceuticals, acute coronary syndromes, atrial fibrillation, bacterial infections, healthcare providers, global market, commercialization, partnerships, licensing agreements, innovative treatments.